8-K: Oragenics, Inc. Implements One-for-Thirty Reverse Stock Split to Maintain NYSE American Listing

Oragenics, Inc. announced a 1-for-30 reverse stock split, effective June 3, 2025, to meet NYSE American's continued listing standards and increase its share price.

Summary

• Oragenics, Inc. filed Articles of Amendment to its Amended and Restated Articles of Incorporation on May 27, 2025, to effect a One-for-Thirty (1-for-30) reverse stock split of its common stock.
• The reverse stock split is anticipated to become effective at 12:01 a.m. Eastern Time on June 3, 2025, with post-split trading on NYSE American commencing at the open of business on the same day.
• Shareholders approved the reverse stock split at the 2024 Annual Meeting on May 2, 2025, granting the Board discretion to set a ratio between 1-for-5 and 1-for-50.
• The Board of Directors selected the 1-for-30 ratio on May 27, 2025.
• The primary reason for the reverse stock split is to meet NYSE American's continued listing standards and mitigate the risk of delisting due to a low trading price.
• No fractional shares will be issued; instead, any fractional share will be rounded up to the nearest whole share.
• The reverse stock split does not affect the authorized shares of 350,000,000 common stock and 50,000,000 preferred stock.
• Pre-split, as of January 20, 2023, there were 21,475,289 shares of common stock outstanding, which will reduce to approximately 715,843 shares post-split.
• Shareholders' percentage of ownership and proportional voting power will remain virtually unchanged, aside from minor adjustments due to fractional share rounding.
• Proportionate adjustments will be made to the exercise price and number of shares for outstanding stock options and warrants.
• The company's common stock will continue to trade under the symbol OGEN but with a new CUSIP number, 684023 609.

Sentiment

Score: 3

Explanation: The sentiment is generally negative because a reverse stock split is typically a reactive measure to address a low stock price and avoid delisting, indicating past underperformance. While the action itself is a positive step to maintain listing, the underlying reason for it is a concern. The company's stated goal of attracting 'quality-focused investors' is forward-looking and aspirational, not a current positive outcome.

Positives

• The reverse stock split is intended to enable the company to meet NYSE American's continued listing standards, preventing potential delisting.
• Rounding up of fractional shares benefits shareholders who would otherwise receive less than a whole share.
• The action aims to align the company with expectations of long-term, quality-focused investors by increasing share price and reducing share count.

Negatives

• The necessity of a reverse stock split often indicates a significantly low stock price, which is generally a negative signal regarding market perception or financial performance.
• While ownership percentage remains largely unchanged, the reduction in the number of outstanding shares can sometimes be perceived negatively by the market.

Risks

• Risk of delisting from the NYSE American due to the trading price of its Common Stock falling below the exchange's minimum price requirement.

Future Outlook

The company anticipates that the reverse stock split will increase the market price per share of its common stock, enabling it to meet NYSE American's continued listing standards and potentially attract long-term, quality-focused investors.

Management Comments

• "The reverse split reinforces our commitment to strengthening our capital markets presence."
• "By increasing our share price and reducing share count, we believe well be better aligned with the expectations of long-term, quality-focused investors who share our vision for transforming neurological care."

Industry Context

Reverse stock splits are a common measure taken by companies, particularly in the biotechnology sector, when their stock price falls below exchange minimums. This action by Oragenics reflects a strategic move to maintain its listing on a major exchange, which is crucial for liquidity and investor confidence, especially for clinical-stage companies reliant on capital markets for funding their R&D efforts in neurological disorders.

Comparison to Industry Standards

• Reverse stock splits are a common corporate action for companies, particularly those in the biotechnology sector, when their share price falls below exchange minimums.
• While the document does not provide specific comparable companies or projects, the decision to undertake a reverse split to maintain exchange listing is a standard practice observed across various industries.
• The 1-for-30 ratio is within the typical range for such actions, and the rounding up of fractional shares is a shareholder-friendly approach often adopted in these scenarios.

Corporate Governance

Stakeholder Impact

• Shareholders: Their total number of shares will decrease by a factor of 30, but their percentage of ownership and proportional voting power will remain virtually unchanged (except for minor adjustments due to fractional share rounding up). The per-share price is expected to increase.
• Investors (potential): The increased share price and continued NYSE American listing may make the stock more attractive to institutional and long-term investors who have minimum price requirements or prefer exchange-listed securities.
• Employees (with stock options/warrants): Their stock options and warrants will be proportionately adjusted in terms of exercise price and number of shares, maintaining their intrinsic value.

Next Steps

• Common Stock to begin trading on a split-adjusted basis on NYSE American at the open of business on June 3, 2025.
• Transfer agent (Continental Stock Transfer & Trust Company) will provide instructions to shareholders regarding the process for exchanging shares.

Key Dates

Recommendation

Keywords

Oragenics, OGEN, Reverse Stock Split, NYSE American, Stock Listing, Biotechnology, Neurological Disorders, ONP-002, Concussion Treatment, Capital Markets, Share Price, Corporate Governance